Camylofin is a newly developed drug meant to treat chronic pain resulting from conditions like arthritis, back injuries and nerve damage. Manufactured by Neureka Pharmaceuticals, camylofin works through a novel mechanism of action that helps address pain in a more targeted way than existing medications.
How Does Camylofin Work?
Camylofin works by blocking the function of a protein called Neurokinin B (NKB) which plays a key role in modulating pain signals within the nervous system. Under normal circumstances, NKB helps transmit pain sensations from sites of injury to the brain. However, during chronic pain situations, NKB levels tend to rise excessively leading to amplification of pain signals beyond what's needed for protection.
By selectively inhibiting NKB, Camylofin helps prevent the over-amplification of pain without impacting other important neurological processes. This allows it to provide pain relief without the side effects seen with older opioid medications which act on different pain pathways in less targeted ways.
Clinical Trial Results
Neureka Pharmaceuticals recently completed Phase 3 clinical trials involving over 1000 patients with chronic pain from various causes. The trials focused on evaluating camylofin's efficacy, safety and tolerability when used over a 12 week period.
The results showed camylofin providing statistically significant reductions in pain levels compared to placebo as measured on standard pain rating scales. Nearly 60% of patients reported feeling moderate to complete relief of their chronic pain symptoms while on camylofin. Importantly, camylofin was also quite well-tolerated with minimal side effects seen.
Fewer Side Effects than Opioids
One of the major advantages of camylofin highlighted in the clinical studies was its superior side effect and safety profile compared to commonly used opioid painkillers. Adverse effects like nausea, vomiting, drowsiness and cognitive impairment were far less frequent with camylofin.
Only about 10-15% of patients reported minor issues like headache or gastrointestinal upset with camylofin compared to over 50% of patients experiencing one or more side effects from opioids. Importantly, camylofin did not lead to issues of tolerance, dependence or abuse potential seen as major problems with chronic opioid use.
Potential Role in Pain Management
Based on the efficacy and safety data from trials, camylofin is expected to play an important role as a new treatment option for managing chronic pain, especially for patients who either do not get relief or cannot tolerate standard opioid therapies.
Doctors will be able to incorporate camylofin into a multimodal pain management regimen using it along with physical therapy, lifestyle changes and other non-pharmacological interventions. This would help minimize reliance on opioids for chronic pain and reduce their negative health impacts.
Expected Availability and Costs
Subject to FDA approval expected in early 2023, camylofin will be commercially launched in the US market by mid-2023. Neureka Pharma plans to price camylofin competitively around $500-600 for a month's supply which would be comparable to costs of newer opioid alternatives and much lower than costly biologic treatments.
With use of patient assistance programs, most insurance formularies are expected to provide reasonable copays making camylofin an affordable option for appropriate chronic pain patients.
Get this Report in Japanese Language- カミロフィン
Get this Report in Korean Language- 카밀로핀
About Author-
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)
